Delisting riskPopularity #4,698
Impact BioMedical (IBO)
Commercializes health-and-wellness patents and Celios air-purification products.
$6.60
vs last close−0.06 (−0.88%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 1 | 26 | 1 | 1 | 1 | 1 | 2 | 1 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 0 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | −1 | −1 | −1 | −26 | −1 | −1 | −1 | −1 | −2 | −1 |
| 0 | 0 | 0 | 5 | −1 | 0 | −13 | −1 | 4 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | −6 | 1 | 0 | 13 | 0 | −4 | 0 | 0 |
| Income before tax | −1 | −1 | −1 | 4 | −27 | −1 | −14 | −1 | 3 | −2 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −3 | 0 | 0 |
| Net income from continuing operations | −1 | −1 | −1 | 4 | −27 | −1 | −14 | −1 | 5 | −2 | −1 |
| Net income | −1 | −1 | −1 | 4 | −27 | −1 | −14 | −1 | 5 | −2 | −1 |
| EPS, basic | −$0.11 | −$0.08 | −$0.08 | $0.37 | −$2.36 | −$0.10 | −$1.18 | −$0.12 | $0.05 | −$0.02 | −$0.01 |
| EPS, diluted | −$0.11 | −$0.08 | −$0.08 | $0.06 | −$2.36 | −$0.10 | −$1.18 | −$0.12 | $0.05 | −$0.02 | −$0.01 |
| Weighted average shares, basic | 12 | 12 | 12 | 72 | 12 | 12 | 12 | 12 | 32 | 108 | 108 |
| Weighted average shares, diluted | 12 | 12 | 12 | 72 | 12 | 12 | 12 | 12 | 32 | 108 | 108 |
| EBITDA | −1 | 0 | 0 | 5 | −27 | −1 | −14 | −1 | 3 | −2 | 0 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | 5 | −27 | −1 | −14 | −1 | 3 | −2 | −1 |